Sjögren's disease & overlap diseases
Impact of disease duration on systemic clinical profile in Sjogren’s syndrome
Authors' conclusion
In summary, disease duration serves as a crucial determinant for the prognosis of patients with pSS.
Study context
- Population
- Patients with Primary Sjogren's Syndrome (pSS) (mean [SD] age 53.1 [24] years), Peking University People's Hospital, January 2015–December 2022
- Participants
- 3,978 patients
- Exposure
- pSS patients grouped by disease duration
- Outcome
- Patients with WBC decrease
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Observational data: associations, not effects.
Further findings
Hemoglobin (HGB) and platelet (PLT) decrease
- Robustly associated with extended disease duration
- P < 0.0001
Systemic involvement (skin, joint, lung, nervous system)
- Incidence rates strikingly increased in each group with disease progression
Comorbid conditions (e.g. diabetes, tumors)
- Higher likelihood with long-term pSS
Original publication
Impact of disease duration on systemic clinical profile in Sjogren’s syndrome. Arthritis Res Ther. Published 24 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →